Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock
Primary Purpose
Septic Shock
Status
Unknown status
Phase
Not Applicable
Locations
Tunisia
Study Type
Interventional
Intervention
Microdialysis Probe (Muscle microdialysis)
Dobutamine
Levosimendan
Sponsored by
About this trial
This is an interventional screening trial for Septic Shock
Eligibility Criteria
Inclusion Criteria:
- patients who fulfilled the criteria of septic shock that required norepinephrine (NE) to maintain a mean arterial pressure (MAP) of at least 65 mm Hg despite appropriate volume resuscitation (pulmonary arterial occlusion pressure [PAOP] = 12 to 18 mm Hg and central venous pressure [CVP] = 8 to 12 mm Hg)
Exclusion Criteria:
- pregnancy, uncontrolled hemorrhage, terminal heart failure, significant valvular heart disease, documented or suspected acute coronary syndrome, and a limitation on the use of inotropes: left ventricle outflow obstruction, systolic anterior motion of the mitral valve.
Sites / Locations
- Military Hopital of TunisRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
levosimendan 0.2 μg/kg/min
dobutamine 5 μg/kg/min
Arm Description
Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus). Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle.
Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period. Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle.
Outcomes
Primary Outcome Measures
changes in the concentration of glucose(mmol/l) in the extracellular fluid of the skeletal muscle
changes in the concentration of lactate(mmol/l) in the extracellular fluid of the skeletal muscle
changes in the concentration of pyruvate (µmol/l) in the extracellular fluid of the skeletal muscle
changes in the concentration of glycerol (µmol/l) in the extracellular fluid of the skeletal muscle
Secondary Outcome Measures
Full Information
NCT ID
NCT02963454
First Posted
November 4, 2016
Last Updated
February 8, 2018
Sponsor
Military Hospital of Tunis
1. Study Identification
Unique Protocol Identification Number
NCT02963454
Brief Title
Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock
Official Title
Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock: A Randomised Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Unknown status
Study Start Date
January 2011 (undefined)
Primary Completion Date
February 2018 (Anticipated)
Study Completion Date
February 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Military Hospital of Tunis
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate changes in the concentration of glucose, lactate, pyruvate and glycerol in the extracellular fluid of the skeletal muscle following levosimendan administration in patients with septic shock.
Detailed Description
The study was designed as a prospective, double-blind, controlled, clinical trial and performed in a multidisciplinary intensive care unit. After achieving normovolemia and a mean arterial pressure of at least 65 mmHg, 20 septic shock patients were randomized to receive either levosimendan 0.2 μg/kg/min, or dobutamine 5 μg/kg/min. Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis. All measurements, including data from right heart catheterization were obtained at baseline and every 6 hours for the following 72 hours after randomization.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
levosimendan 0.2 μg/kg/min
Arm Type
Experimental
Arm Description
Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus).
Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle.
Arm Title
dobutamine 5 μg/kg/min
Arm Type
Active Comparator
Arm Description
Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period.
Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle.
Intervention Type
Device
Intervention Name(s)
Microdialysis Probe (Muscle microdialysis)
Intervention Description
Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.
During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.
Intervention Type
Drug
Intervention Name(s)
Dobutamine
Other Intervention Name(s)
DOBUTREX
Intervention Description
Dobutamine (5 μg/kg/min) will be used as indicated
Intervention Type
Drug
Intervention Name(s)
Levosimendan
Other Intervention Name(s)
SIMDAX
Intervention Description
Levosimendan (0.2 μg/kg/min) will be used as indicated
Primary Outcome Measure Information:
Title
changes in the concentration of glucose(mmol/l) in the extracellular fluid of the skeletal muscle
Time Frame
At baseline and then every six hours for the following 72 hours after randomization.
Title
changes in the concentration of lactate(mmol/l) in the extracellular fluid of the skeletal muscle
Time Frame
At baseline and then every six hours for the following 72 hours after randomization.
Title
changes in the concentration of pyruvate (µmol/l) in the extracellular fluid of the skeletal muscle
Time Frame
At baseline and then every six hours for the following 72 hours after randomization.
Title
changes in the concentration of glycerol (µmol/l) in the extracellular fluid of the skeletal muscle
Time Frame
At baseline and then every six hours for the following 72 hours after randomization.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients who fulfilled the criteria of septic shock that required norepinephrine (NE) to maintain a mean arterial pressure (MAP) of at least 65 mm Hg despite appropriate volume resuscitation (pulmonary arterial occlusion pressure [PAOP] = 12 to 18 mm Hg and central venous pressure [CVP] = 8 to 12 mm Hg)
Exclusion Criteria:
pregnancy, uncontrolled hemorrhage, terminal heart failure, significant valvular heart disease, documented or suspected acute coronary syndrome, and a limitation on the use of inotropes: left ventricle outflow obstruction, systolic anterior motion of the mitral valve.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
zied hajjej
Phone
20358907
Email
hajjej_zied@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
mustapha ferjani
Phone
98329256
Email
mustapha.ferjani@planet.tn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
mustapha ferhjani
Organizational Affiliation
Department of C ritical C are Medicine and Anesthesiology, Military Hospital of Tunis, Tunisia, Tunis, Tunisia
Official's Role
Study Director
Facility Information:
Facility Name
Military Hopital of Tunis
City
Tunis
ZIP/Postal Code
1008
Country
Tunisia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zied hajjej
Phone
20358907
Ext
00216
Email
hajjej_zied@hotmail.com
First Name & Middle Initial & Last Name & Degree
mustapha ferjani
Phone
98329256
Ext
00216
Email
mustapha.ferjani@planet.tn
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
via emails
Citations:
PubMed Identifier
28234790
Citation
Hajjej Z, Meddeb B, Sellami W, Labbene I, Morelli A, Ferjani M. Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock: A Randomized Controlled Pilot Study. Shock. 2017 Sep;48(3):307-312. doi: 10.1097/SHK.0000000000000851.
Results Reference
derived
Learn more about this trial
Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock
We'll reach out to this number within 24 hrs